Tina Moore

That is not the same thing as what's being discussed anywhere that I'm seeing in the medical articles that I'm reading, in the big publications that continue to interview other doctors who steal my verbiage and literally plagiarize my words. And I get zero credit. And that's okay.

That is not the same thing as what's being discussed anywhere that I'm seeing in the medical articles that I'm reading, in the big publications that continue to interview other doctors who steal my verbiage and literally plagiarize my words. And I get zero credit. And that's okay.

That is not the same thing as what's being discussed anywhere that I'm seeing in the medical articles that I'm reading, in the big publications that continue to interview other doctors who steal my verbiage and literally plagiarize my words. And I get zero credit. And that's okay.

Chaps my height a little bit, but what I think more notably chops my height is the fact that they're just getting it completely wrong. So let's dive into this one. So the following scenarios should be considered for clinical application of microdosing. First of all, just to back up, they talk about the surge in demand for GLP-1s has resulted in intermittent global shortages and gaps in therapy.

Chaps my height a little bit, but what I think more notably chops my height is the fact that they're just getting it completely wrong. So let's dive into this one. So the following scenarios should be considered for clinical application of microdosing. First of all, just to back up, they talk about the surge in demand for GLP-1s has resulted in intermittent global shortages and gaps in therapy.

Chaps my height a little bit, but what I think more notably chops my height is the fact that they're just getting it completely wrong. So let's dive into this one. So the following scenarios should be considered for clinical application of microdosing. First of all, just to back up, they talk about the surge in demand for GLP-1s has resulted in intermittent global shortages and gaps in therapy.

Maybe somebody's gotten acutely ill and they can't take their full dose or maybe they've been in the hospital or maybe... different scenarios where they might need to use a smaller dose than what they're normally doing. Maybe they need to make their pens last longer because they can't access it. There's all different kinds of issues here. Cost, obviously, access would be the two big ones.

Maybe somebody's gotten acutely ill and they can't take their full dose or maybe they've been in the hospital or maybe... different scenarios where they might need to use a smaller dose than what they're normally doing. Maybe they need to make their pens last longer because they can't access it. There's all different kinds of issues here. Cost, obviously, access would be the two big ones.

Maybe somebody's gotten acutely ill and they can't take their full dose or maybe they've been in the hospital or maybe... different scenarios where they might need to use a smaller dose than what they're normally doing. Maybe they need to make their pens last longer because they can't access it. There's all different kinds of issues here. Cost, obviously, access would be the two big ones.

And what they propose is transitioning between a GLP-1 vaccine Receptor agonist, microdosing can help patients transition to a new GLP-1 receptor agonist through gradual dose adjustments to improve therapeutic response. I would agree with that. Dose escalation or de-escalation, microdosing supports a controlled titration or taper to safely adjust for necessary dose changes.

And what they propose is transitioning between a GLP-1 vaccine Receptor agonist, microdosing can help patients transition to a new GLP-1 receptor agonist through gradual dose adjustments to improve therapeutic response. I would agree with that. Dose escalation or de-escalation, microdosing supports a controlled titration or taper to safely adjust for necessary dose changes.

And what they propose is transitioning between a GLP-1 vaccine Receptor agonist, microdosing can help patients transition to a new GLP-1 receptor agonist through gradual dose adjustments to improve therapeutic response. I would agree with that. Dose escalation or de-escalation, microdosing supports a controlled titration or taper to safely adjust for necessary dose changes.

Poor tolerability for patients with severe GI side effects starting with Microdosing and increasing slowly can improve tolerability and prevent therapeutic disruption. And for cash payers or people who are paying out of pocket, maybe they can extend the life of their pen, reducing the cost. So again, they're pretty much using this as an on-ramping method. It's not a microdose.

Poor tolerability for patients with severe GI side effects starting with Microdosing and increasing slowly can improve tolerability and prevent therapeutic disruption. And for cash payers or people who are paying out of pocket, maybe they can extend the life of their pen, reducing the cost. So again, they're pretty much using this as an on-ramping method. It's not a microdose.

Poor tolerability for patients with severe GI side effects starting with Microdosing and increasing slowly can improve tolerability and prevent therapeutic disruption. And for cash payers or people who are paying out of pocket, maybe they can extend the life of their pen, reducing the cost. So again, they're pretty much using this as an on-ramping method. It's not a microdose.

It might be, but it's... not in the application i was trying to discuss it for but that's neither here nor there we're just trying to help people out the most exciting part is this on page two of this very short opinion piece is a whole chart it's a graphic and this is why i'm excited you guys We can use the pens to microdose. We can use the pens to microdose. It's called the pen click method.

It might be, but it's... not in the application i was trying to discuss it for but that's neither here nor there we're just trying to help people out the most exciting part is this on page two of this very short opinion piece is a whole chart it's a graphic and this is why i'm excited you guys We can use the pens to microdose. We can use the pens to microdose. It's called the pen click method.

It might be, but it's... not in the application i was trying to discuss it for but that's neither here nor there we're just trying to help people out the most exciting part is this on page two of this very short opinion piece is a whole chart it's a graphic and this is why i'm excited you guys We can use the pens to microdose. We can use the pens to microdose. It's called the pen click method.

I just read about it a few weeks ago in an article on Medline, I think it was. And then they referred to an article from a few years back when they were talking about this pen click method, which I've never heard of, where you just dial the pen a certain amount of clicks to get the dose that you're looking for. And based on the amount of clicks, they give you the actual dosage that that would be.

I just read about it a few weeks ago in an article on Medline, I think it was. And then they referred to an article from a few years back when they were talking about this pen click method, which I've never heard of, where you just dial the pen a certain amount of clicks to get the dose that you're looking for. And based on the amount of clicks, they give you the actual dosage that that would be.